Literature DB >> 750118

Circulating IgG complexes in primary biliary cirrhosis. A serial study in forty patients followed for two years.

R C Gupta, E R Dickson, F C McDuffie, A H Baggenstoss.   

Abstract

Several antibodies are present in sera of patients with primary biliary cirrhosis (PBC). We have looked for evidence of antigen-antibody complexes in sera of PBC assuming that some of the antibodies may circulate complexed with an antigen. The Raji cell radioimmunoassay, which determines complement-bound immune complexes, was used to determine the levels of such complexes in serial samples of sera from forty patients with PBC followed for 2 years. Twenty-four patients (60%) were found to have significantly elevated levels of circulating complexes. In the majority they were detected from the beginning of the study and the high levels persisted. In seven patients whose sera initially had normal levels of complexes, the levels increased to become abnormal during the following year. These complexes sedimented at greater than or equal to 19S in the majority of patients studied. The mean level of C3 but not C4 was lower in patients with elevated complexes than in those with normal complexes. A significant correlation was observed between the presence of elevated complexes and the severity of the inflammatory cell infiltrate surrounding intrahepatic portal tracts and serum IgG and IgM levels. There was also a significant correlation with titres of antimitochondrial antibody, but not with the histological stage of disease or with the collagen and copper content of the liver. Although the method of detection of immune complexes is indirect and the antigen is unknown, the presence of such high levels of complexes suggests a possible role of immune complexes in the pathogenesis of PBC.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 750118      PMCID: PMC1537455     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  IMMUNOCYTOCHEMICAL AND SEROLOGIC OBSERVATIONS IN PRIMARY BILIARY CIRRHOSIS.

Authors:  F PARONETTO; F SCHAFFNER; H POPPER
Journal:  N Engl J Med       Date:  1964-11-26       Impact factor: 91.245

2.  THE PATHOLOGY OF PRIMARY BILIARY CIRRHOSIS WITH EMPHASIS ON HISTOGENESIS.

Authors:  A H BAGGENSTOSS; W T FOULK; H R BUTT; R C BAHN
Journal:  Am J Clin Pathol       Date:  1964-09       Impact factor: 2.493

3.  Antinuclear factor and other antibodies in blood and liver diseases.

Authors:  E J HOLBOROW; G L ASHERSON; G D JOHNSON; R D BARNES; D S CARMICHAEL
Journal:  Br Med J       Date:  1963-03-09

4.  Bile canalicular antibody in primary biliary cirrhosis and in other liver diseases.

Authors:  R N MacSween; E M Armstrong; K G Gray; M Mason
Journal:  Lancet       Date:  1973-06-23       Impact factor: 79.321

5.  Immunological and histological studies in primary biliary cirrhosis.

Authors:  S Hadziyannis; P J Scheuer; T Feizi; R Naccarato; D Doniach; S Sherlock
Journal:  J Clin Pathol       Date:  1970-03       Impact factor: 3.411

6.  Circulating conversion products of C3 in liver disease. Evidence for in vivo activation of the complement system.

Authors:  P Teisberg; E Gjone
Journal:  Clin Exp Immunol       Date:  1973-08       Impact factor: 4.330

Review 7.  Autoimmunity in liver diseases.

Authors:  D Doniach
Journal:  Prog Clin Immunol       Date:  1972

8.  Complement in pericardial fluid of lupus erythematosus. Studies in two patients.

Authors:  G G Hunder; B J Mullen; F C McDuffie
Journal:  Ann Intern Med       Date:  1974-04       Impact factor: 25.391

9.  Binding of soluble immune complexes to Raji lymphocytes. Role of receptors for complement components, C1q and C3-C3b.

Authors:  R C Gupta; F C McDuffie; G Tappeiner; R E Jordon
Journal:  Immunology       Date:  1978-04       Impact factor: 7.397

10.  Serum complement in chronic liver disease.

Authors:  B J Potter; A M Trueman; E A Jones
Journal:  Gut       Date:  1973-06       Impact factor: 23.059

View more
  11 in total

Review 1.  Primary biliary cirrhosis.

Authors:  D R Triger
Journal:  Br Med J (Clin Res Ed)       Date:  1982-06-26

2.  Preciitating antibodies to mitochondrial antigens in patients with primary biliary cirrhosis.

Authors:  K Miyachi; R C Gupta; E R Dickson; E M Tan
Journal:  Clin Exp Immunol       Date:  1980-03       Impact factor: 4.330

3.  Identification of biliary antigens in circulating immune complexes in primary biliary cirrhosis.

Authors:  P Amoroso; D Vergani; B M Wojcicka; I G McFarlane; A L Eddleston; D E Tee; R Williams
Journal:  Clin Exp Immunol       Date:  1980-10       Impact factor: 4.330

4.  Localisation of immunoglobulin on the liver cell surface in primary biliary cirrhosis.

Authors:  K Krogsgaard; U Tage-Jensen; P Wantzin; J Aldershvile; F Hardt
Journal:  J Clin Pathol       Date:  1981-10       Impact factor: 3.411

5.  An association between primary biliary cirrhosis and jejunal villous atrophy resembling celiac disease.

Authors:  G D Iliffe; D A Owen
Journal:  Dig Dis Sci       Date:  1979-10       Impact factor: 3.199

6.  Isolation of circulating immune complexes by conglutinin and separation of antigen from dissociated complexes by immobilized protein A.

Authors:  R C Gupta; E M Tan
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

7.  IgA containing circulating immune complexes and IgA anti-single stranded DNA antibodies in patients with obstructive jaundice.

Authors:  G Ohshio; F Furukawa; K Sekita; T Manabe; T Tobe; Y Hamashima
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

8.  Lymphocytotoxic antibodies in primary biliary cirrhosis.

Authors:  A Parés; J Martorell; J Caballería; J Vives; M Bruguera; J Rodés
Journal:  Dig Dis Sci       Date:  1985-09       Impact factor: 3.199

9.  Mononuclear cell complement receptor blockade in primary biliary cirrhosis.

Authors:  M N Al-Aghbar; J Neuberger; R Williams; A L Eddleston
Journal:  Gut       Date:  1985-01       Impact factor: 23.059

10.  Complement profile in primary biliary cirrhosis.

Authors:  M Schlesinger; C Benbassat; Y Shoenfeld
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.